Large-scale Production of Novel Porcine Circovirus Type 2d (PCV2d)
Subunit Vaccine Using E. coli Platform
Abstract
Porcine Circovirus type 2d (PCV2d) is becoming the predominant PCV
genotype and considerably affects the global pig industry. Nevertheless,
currently no commercial PCV2d vaccine is available. Preventing and
controlling the disease caused by PCV2d is therefore based on other
genotype-based vaccines. However, their production platforms are
laborious, limited in expression level and relatively expensive for
veterinary applications. To address these challenges, we have developed
a simple and cost-efficient platform for a novel PCV2d vaccine
production platform, using fed-batch E. coli fermentation followed by
cell disruption and filtration, and a single purification step via
cation exchange chromatography. The process was developed at bench scale
and then pilot scale where the PCV2d subunit protein yield was
approximately 0.8 g/L fermentation volume in a short production time.
Moreover, we have successfully implemented this production process at
two different sites, in Southeast Asia and Europe. This demonstrates
transferability and the high potential for successful industrial
production.